[go: up one dir, main page]

SK6542002A3 - The use of antibodies for the production of pharmaceutical composition useful as vaccines - Google Patents

The use of antibodies for the production of pharmaceutical composition useful as vaccines Download PDF

Info

Publication number
SK6542002A3
SK6542002A3 SK654-2002A SK6542002A SK6542002A3 SK 6542002 A3 SK6542002 A3 SK 6542002A3 SK 6542002 A SK6542002 A SK 6542002A SK 6542002 A3 SK6542002 A3 SK 6542002A3
Authority
SK
Slovakia
Prior art keywords
antibodies
tumor
individual
antibody
associated antigens
Prior art date
Application number
SK654-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Hans Loibner
Helmut Eckert
Gottfried Himmler
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Publication of SK6542002A3 publication Critical patent/SK6542002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK654-2002A 1999-11-16 2000-11-15 The use of antibodies for the production of pharmaceutical composition useful as vaccines SK6542002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0192799A AT409086B (de) 1999-11-16 1999-11-16 Neue verwendung von antikörpern als impfstoffe
PCT/EP2000/011306 WO2001035989A2 (fr) 1999-11-16 2000-11-15 Nouvelle utilisation d'anticorps en tant que vaccins

Publications (1)

Publication Number Publication Date
SK6542002A3 true SK6542002A3 (en) 2002-11-06

Family

ID=3524036

Family Applications (1)

Application Number Title Priority Date Filing Date
SK654-2002A SK6542002A3 (en) 1999-11-16 2000-11-15 The use of antibodies for the production of pharmaceutical composition useful as vaccines

Country Status (24)

Country Link
EP (1) EP1229936B1 (fr)
JP (1) JP2003514028A (fr)
KR (1) KR20020060968A (fr)
CN (1) CN1390138A (fr)
AT (1) AT409086B (fr)
AU (1) AU780853B2 (fr)
BR (1) BR0015597A (fr)
CA (1) CA2391927A1 (fr)
CZ (1) CZ20021707A3 (fr)
DE (1) DE50006526D1 (fr)
DK (1) DK1229936T3 (fr)
EE (1) EE200200252A (fr)
ES (1) ES2218272T3 (fr)
HU (1) HUP0204216A2 (fr)
IL (1) IL149614A0 (fr)
IS (1) IS6381A (fr)
MX (1) MXPA02004942A (fr)
NO (1) NO20022333L (fr)
NZ (1) NZ518669A (fr)
PL (1) PL356770A1 (fr)
PT (1) PT1229936E (fr)
SK (1) SK6542002A3 (fr)
TR (1) TR200401267T4 (fr)
WO (1) WO2001035989A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017108A (en) * 1975-04-17 1977-04-12 Archibald Kenrick And Sons Limited Window stay
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US20070048795A1 (en) * 2005-08-26 2007-03-01 Xiangming Fang Immunoaffinity separation and analysis compositions and methods
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002848A1 (fr) * 1983-01-28 1984-08-02 Centocor Inc Anticorps anti-idiotypiques aux recepteurs antigenes des cellules t
JPH03501209A (ja) * 1988-05-17 1991-03-22 フェロン、ソルダノ 抗ヒト高分子量メラノーマ関連抗原に対する抗イディオタイプ抗体
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
JPH07504683A (ja) * 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
DK0800578T3 (da) * 1994-12-28 2003-08-11 Univ Kentucky Rekombinant monoklonalt anti-idiotype antistof 3H1

Also Published As

Publication number Publication date
NO20022333D0 (no) 2002-05-15
CZ20021707A3 (cs) 2002-10-16
WO2001035989A3 (fr) 2001-10-04
WO2001035989A2 (fr) 2001-05-25
ES2218272T3 (es) 2004-11-16
TR200401267T4 (tr) 2004-07-21
EE200200252A (et) 2003-06-16
CA2391927A1 (fr) 2001-05-25
ATA192799A (de) 2001-10-15
AU780853B2 (en) 2005-04-21
IS6381A (is) 2002-05-14
IL149614A0 (en) 2002-11-10
NZ518669A (en) 2003-08-29
EP1229936B1 (fr) 2004-05-19
MXPA02004942A (es) 2003-10-14
BR0015597A (pt) 2002-07-23
CN1390138A (zh) 2003-01-08
EP1229936A2 (fr) 2002-08-14
DE50006526D1 (de) 2004-06-24
AU2357201A (en) 2001-05-30
HUP0204216A2 (en) 2003-04-28
PT1229936E (pt) 2004-09-30
NO20022333L (no) 2002-06-03
DK1229936T3 (da) 2004-08-30
KR20020060968A (ko) 2002-07-19
PL356770A1 (en) 2004-07-12
JP2003514028A (ja) 2003-04-15
AT409086B (de) 2002-05-27

Similar Documents

Publication Publication Date Title
US8444974B2 (en) Use of antibodies for the vaccination against cancer
KR20020011137A (ko) 면역 반응을 개시시키기 위해 다중 에피토프 항원의입체형태를 변화시키기 위한 방법 및 조성물
SK6542002A3 (en) The use of antibodies for the production of pharmaceutical composition useful as vaccines
Roehnisch et al. Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model
SK11732003A3 (sk) Spôsob výroby očkovacej látky
EP1618890B1 (fr) Utilisation d'anticorps en très faibles doses pour vaccination contre le cancer
US20040265318A1 (en) Use of antibodies for the vaccination against cancer
JP2001055341A (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物
KR20000011003A (ko) 면역 반응을 개시시키기 위해 다중 에피토프 항원의 입체형태를변화시키기 위한 방법 및 조성물
JP2004002481A (ja) 免疫応答を惹起するための、多数エピトープ含有抗原の再構成法および組成物

Legal Events

Date Code Title Description
FC9A Refused patent application